Is Clonazepam Safe During Pregnancy? Risks Explained

Clonazepam is not considered clearly safe during pregnancy, but the evidence against it is less alarming than many people assume. The available studies have not found a strong link between clonazepam alone and major birth defects, though the data remain limited and other risks, including preterm birth and short-term effects on the newborn, deserve attention. The picture is complicated further by the fact that the conditions clonazepam treats, such as panic disorder and epilepsy, can themselves pose risks to a pregnancy when left untreated.

What the Evidence Says About Birth Defects

The fear that benzodiazepines cause structural birth defects dates back decades, with early case reports suggesting a possible link to oral clefts. More recent and better-designed studies have been more reassuring, at least for clonazepam specifically. A study tracking pregnancies exposed to clonazepam monotherapy found no increase in major malformations, though the researchers cautioned that the sample was too small to rule out a modest risk with confidence.¹ Data from the Massachusetts General Hospital National Pregnancy Registry offered additional reassurance: roughly 3% of infants exposed to benzodiazepines in the first trimester had a major malformation, which was virtually identical to the rate in unexposed pregnancies.²

That said, most of the available studies are observational and limited in size. A large Scandinavian cohort that looked at ten antiepileptic drugs across nearly two million pregnancies included fewer than a thousand clonazepam-exposed pregnancies, which limits the statistical power to detect rare malformations.³ Compare that to drugs like valproic acid, which has been studied in thousands of exposed pregnancies and is now known to carry a meaningful risk of neural tube defects. Clonazepam simply has not been studied at that scale. The honest summary is that available data do not show an increased malformation risk, but the data are not large enough to guarantee safety either.

Miscarriage Risk

A concern that receives less attention than birth defects is whether benzodiazepines raise the chance of miscarriage. A recent systematic review and meta-analysis pooled data from studies of the most commonly used benzodiazepines in pregnancy, including clonazepam, lorazepam, and alprazolam. The pooled odds of miscarriage for these individual agents ranged from about 1.4 to 1.8 times higher than in unexposed pregnancies, and the consistency across different drugs suggested this could be a class-wide effect rather than something unique to one particular benzodiazepine.⁴

Interpreting that number requires some care. The women taking benzodiazepines in these studies are not identical to the women not taking them. They tend to have higher rates of anxiety, depression, or other conditions that can themselves affect pregnancy outcomes. Researchers try to adjust for those differences, but residual confounding is hard to fully eliminate. Still, the finding is consistent enough that it warrants a candid conversation with your prescriber if you are taking clonazepam and planning a pregnancy or have just found out you are pregnant.

Preterm Birth and Low Birth Weight

The timing of benzodiazepine exposure during pregnancy appears to matter a great deal for certain outcomes. A large study using sibling comparisons, which helps control for family-level factors that run across pregnancies, found that the risk of preterm birth and smaller-than-expected babies was significantly elevated only when exposure continued into the third trimester. Specifically, third-trimester exposure was linked to about a 70% higher chance of preterm delivery and roughly a 47% higher chance of the baby being born small for gestational age.⁵

Research on antiepileptic drugs more broadly tells a somewhat similar story, though the details get complicated by the underlying condition. A population-based study found that antiepileptic drug exposure was associated with higher rates of preterm birth and low birth weight overall. But when the researchers separated women who had epilepsy from women taking these drugs for other reasons, the preterm birth link disappeared for women with epilepsy, suggesting the seizure disorder itself, rather than the medication, might be the driver in that group. The link to low birth weight, however, persisted regardless of whether the mother had epilepsy.⁶ The practical takeaway is that third-trimester exposure deserves the closest scrutiny, and your care team may try to minimize the dose or duration during that window if it is clinically feasible.

Effects on the Newborn After Delivery

When a pregnant person takes benzodiazepines close to delivery, the drug is present in the newborn’s system at birth. Because the baby no longer receives the drug through the placenta after the cord is cut, withdrawal-like symptoms can develop in the hours to weeks that follow. A review of neonatal adaptation issues after maternal prescription drug use describes possible symptoms including feeding difficulties, tremors, irritability, changes in muscle tone, vomiting, and persistent crying, which can begin anywhere from a few hours to about a month after birth.⁷ These symptoms overlap with what is sometimes called “floppy infant syndrome,” characterized by reduced muscle tone and sedation in the newborn.

That sounds alarming, and it can be stressful for new parents, but the picture is not universally grim. A case series specifically examining clonazepam-exposed pregnancies found no cases of neonatal withdrawal syndrome, no breathing problems, and no temperature regulation issues in the infants.⁸ The discrepancy probably comes down to dose, timing, and whether other medications were involved. Neonatal teams at delivery hospitals are generally aware of these possibilities and can monitor the baby closely when benzodiazepine use is disclosed ahead of time. That disclosure matters: the symptoms are manageable when recognized early, but they can be confusing if the care team does not know about the exposure.

Longer-Term Developmental Concerns in Children

Beyond the newborn period, a question that worries many parents is whether prenatal benzodiazepine exposure leaves lasting marks on a child’s brain development. Benzodiazepines cross the placenta readily and can bind to receptors in the developing fetal brain that are involved in how nerve cells communicate. That biological mechanism is plausible enough to raise concern, but translating it into real-world outcomes has proven difficult.

A systematic review that gathered the available evidence found some signals of higher risk for internalizing problems like anxiety, impaired gross motor skills, lower academic achievement, and traits associated with attention-deficit hyperactivity disorder (ADHD) in children exposed to benzodiazepines before birth. However, the researchers emphasized that results across studies were contradictory and that bias could not be ruled out as an explanation.⁹

A separate meta-analysis looked specifically at autism spectrum disorder (ASD) and ADHD. It found no increased risk of autism associated with gestational benzodiazepine exposure at any point during pregnancy. For ADHD, there was a statistically significant but very small increase in risk, with about a 7% higher rate among exposed children across studies involving millions of pregnancies.¹⁰ A 7% increase from a baseline that is already common means the absolute difference for any individual child is small. And again, the mothers taking benzodiazepines had anxiety, epilepsy, or other conditions that independently affect child development, making it extremely hard to pin the effect on the drug itself rather than the condition or the stress surrounding it.

The Risks of Stopping Treatment

One of the most underappreciated parts of this discussion is what happens when someone stops clonazepam abruptly because they are afraid of harming the pregnancy. Benzodiazepines are associated with physical dependence, and abrupt discontinuation can trigger withdrawal symptoms that range from rebound anxiety and insomnia to, in severe cases, seizures. Clinical guidance recommends a gradual taper rather than sudden cessation to avoid these withdrawal effects.¹¹ Seizures during pregnancy carry serious risks to both the pregnant person and the fetus, including oxygen deprivation and physical injury.

There is also direct evidence that untreated psychiatric illness itself harms pregnancy outcomes. A study comparing pregnant women with panic disorder found that those who went untreated had the worst neonatal outcomes of any group. Nearly 29% of their babies were born preterm, and about 35% had low birth weight. Women who received pharmacotherapy, in contrast, had outcomes similar to healthy controls.¹² This finding does not mean that medication is always the right choice, but it does show that framing the decision as “medication equals risk, no medication equals safety” is misleading. Both paths carry risk, and the right answer depends on the severity of the condition being treated.

How the Drug Reaches the Fetus

Clonazepam passes through the placenta with relative ease, which is why fetal exposure is essentially guaranteed whenever the drug is taken during pregnancy. Once across the placenta, it also crosses the fetal blood-brain barrier and can bind to GABA receptors in the developing brain. Pregnancy itself changes how the body processes the drug: the apparent clearance of clonazepam increases slightly, which means blood levels may drop somewhat over the course of pregnancy even if the dose stays the same.⁹¹³ This has practical implications: some women may notice their symptoms break through during pregnancy, and dose adjustments sometimes become necessary. Any dose change should be guided by your prescriber rather than done independently, since the goal is to use the lowest effective dose while keeping symptoms adequately controlled.

Interestingly, early-stage research has explored whether drug-delivery technology could reduce fetal exposure. One laboratory study tested clonazepam loaded into tiny polymer particles and found that these particles reduced the drug’s transport across a model of the placental barrier, potentially lowering how much reaches the fetus.¹ This is still a long way from clinical use, but it hints at a future where the trade-off between treating the mother and protecting the fetus could become less sharp.

Breastfeeding on Clonazepam

The question of clonazepam safety does not end at delivery. Many new parents want to know whether they can breastfeed while taking the medication. The evidence here is relatively encouraging. A study measuring benzodiazepine levels in breast milk and maternal blood found that clonazepam, along with most other benzodiazepines tested, had a milk-to-plasma ratio below 1, meaning the drug concentration in milk is lower than in the mother’s blood. The relative infant dose was below 10%, a threshold generally considered compatible with breastfeeding, and no abnormalities were observed in the nursing infants.¹⁴

A systematic review from the International League Against Epilepsy’s Women Task Force reached a consistent conclusion, reporting that clonazepam concentrations measured in breastfed infants were very low, on the order of 10% or less of maternal blood levels.¹⁵ That said, newborns metabolize drugs more slowly than adults, and premature infants are even slower. If your baby is premature or has other health concerns, extra monitoring during breastfeeding is reasonable. Signs to watch for include unusual drowsiness, poor feeding, or trouble gaining weight.

How Clonazepam Compares to Other Benzodiazepines in Pregnancy

People sometimes ask whether switching to a different benzodiazepine would be safer. The honest answer is that there is no clearly “safe” benzodiazepine during pregnancy, and the differences among individual drugs in this class are not well-established enough to guide switching decisions on safety grounds alone. The miscarriage meta-analysis noted that several commonly used agents, including lorazepam, clonazepam, and alprazolam, all showed a similarly elevated risk, suggesting this may be a property of the drug class rather than any one member.⁴ Among antiepileptic medications, clonazepam has a more favorable profile than valproic acid, which is well-documented to increase the risk of neural tube defects and developmental delays. If you are taking clonazepam for epilepsy, that comparison matters. For anxiety and panic disorder, alternatives outside the benzodiazepine class, such as certain antidepressants, are sometimes considered during pregnancy, though each of those carries its own set of data and trade-offs.

Practical Steps If You Are Pregnant or Planning a Pregnancy

The decision about clonazepam during pregnancy is genuinely individual, and blanket recommendations do not serve people well. That said, a few practical principles emerge from the evidence:

Do not stop abruptly. Sudden discontinuation risks withdrawal, including seizures in people with epilepsy. A supervised taper is safer than panicking and throwing out the bottle.
Use the lowest effective dose. Because the drug crosses the placenta freely, minimizing the dose reduces fetal exposure. Your doctor may be able to adjust downward, especially if you have been on a stable dose for a while and your symptoms are well-controlled.
Consider the trimester. Third-trimester exposure carries the strongest evidence for preterm birth, growth effects, and neonatal symptoms. If tapering off is possible before the third trimester, that may reduce some of these risks, though it only makes sense if the underlying condition remains controlled.
Disclose use to your delivery team. If you are still taking clonazepam at the time of delivery, letting the obstetric and neonatal staff know allows them to watch for and manage any symptoms in the baby during the first days of life.
Weigh the condition, not just the drug. Untreated panic disorder, severe anxiety, and uncontrolled epilepsy all carry their own pregnancy risks. The goal is to find the path with the best overall balance, not to eliminate all medication risk while ignoring illness risk.

Emerging Research on Reducing Fetal Exposure

One area of active investigation is whether future drug-delivery methods could allow the pregnant person to benefit from clonazepam while limiting how much of it reaches the fetus. Laboratory work using polymer-based nanoparticles showed that loading clonazepam into these particles reduced the drug’s transport across cells that mimic the placental barrier. In theory, this approach could lower fetal brain exposure without reducing the mother’s therapeutic benefit. The technology is still in early development and has not been tested in pregnant humans, but it reflects a growing recognition in pharmacology that the current all-or-nothing framing of drug safety in pregnancy is not the only option. For now, though, the practical reality remains that any clonazepam taken during pregnancy will reach the fetus, and decisions have to be made with that in mind.